A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
NCT01354990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2974
Last updated 2015-08-27
Summary
The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
Sitagliptin (JANUVIA®)
Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2010-05-31
- Completion
- 2010-05-31
More Related Trials
-
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
NCT01357135 ·Status: COMPLETED
-
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
NCT00758069 ·Status: COMPLETED ·Phase: PHASE2
-
Sitagliptin Dose Determination Study
NCT01530178 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus
NCT00425490 ·Status: COMPLETED ·Phase: PHASE3
-
Januvia Re-examination Study (MK-0431-181)
NCT01062048 ·Status: COMPLETED
-
Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes
NCT01378117 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Diabetes After Gastric Bypass With Sitagliptin
NCT01512797 ·Status: COMPLETED ·Phase: NA
-
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
NCT01845831 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
NCT00659711 ·Status: COMPLETED ·Phase: NA
-
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
NCT00813228 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
NCT01065766 ·Status: COMPLETED
-
Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation
NCT01552694 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
NCT00127192 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Sitagliptin in Glycemic Control in Real World
NCT01316835 ·Status: UNKNOWN
-
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
NCT00832624 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)
NCT00730275 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
NCT00704132 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
NCT00449930 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
NCT00411554 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
NCT00813995 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop
NCT02328040 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin
NCT01054118 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes
NCT00790348 ·Status: UNKNOWN
-
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
NCT01398592 ·Status: COMPLETED ·Phase: PHASE4
-
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
NCT00095056 ·Status: COMPLETED ·Phase: PHASE3